Merav Bar, MD
Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
Assistant Professor, Medical Oncology Division, University of Washington
Seattle Cancer Care Alliance
Researchers at the Seattle Cancer Care Alliance (SCCA) have optimized special methods for modifying T cells to target specific cancer cells in patients with blood cancers. These new T-cell therapies are primarily being tested in clinical trials involving patients with highrisk leukemia or lymphoma before or after bone marrow transplant (BMT).
Preventing Relapse in Adults After Allogeneic BMT for Lymphoid Malignancies
Approved by the FDA last year, CD19-specific Donor T Cells for B-Cell Malignancies After Allogeneic Transplant is a phase I/II trial designed to boost the graft-versus-tumor effect in subgroups of adults with acute lymphocytic leukemia, chronic lymphocytic leukemia, or diffuse large B-cell lymphoma who have received an allogeneic BMT from a matched related donor, thereby reducing the risk of posttransplant relapse.
Preventing or Treating Relapse After BMT for AML, MDS, or CML
This phase I/II trial has two arms: (1) prophylactic T-cell therapy for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML) patients with high risk of relapse after BMT, and (2) treatment with T cells for AML/MDS/ CML patients with either minimal residual disease or full hematologic relapse after BMT.
... to read the full story